We found that the triple-treatment strategy using dexamethasone, RK-20449 and ABT-199 was highly effective in targeting the otherwise resistant MLL-ALL cells in vitro and vivo. Moreover, normal human HSCs and T-cells were not affected by this drug treatment protocol. Here, KMT2A is linked to acute lymphoblastic leukemia.